Zurich Insurance Group Ltd FI purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,382 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,925,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. US Bancorp DE boosted its position in Jazz Pharmaceuticals PLC by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 368 shares during the period. Envestnet Asset Management Inc. boosted its position in Jazz Pharmaceuticals PLC by 43.0% during the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 295 shares during the period. Gargoyle Investment Advisor L.L.C. bought a new stake in Jazz Pharmaceuticals PLC during the second quarter worth approximately $206,000. Janney Montgomery Scott LLC bought a new stake in Jazz Pharmaceuticals PLC during the second quarter worth approximately $211,000. Finally, Brighton Jones LLC bought a new stake in Jazz Pharmaceuticals PLC during the second quarter worth approximately $213,000. 88.34% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/zurich-insurance-group-ltd-fi-purchases-shares-of-12382-jazz-pharmaceuticals-plc-jazz/1617717.html.

In other Jazz Pharmaceuticals PLC news, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction on Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of Jazz Pharmaceuticals PLC stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $160.00, for a total value of $732,800.00. Following the completion of the transaction, the executive vice president now directly owns 32,322 shares of the company’s stock, valued at $5,171,520. The disclosure for this sale can be found here. Insiders sold a total of 9,297 shares of company stock valued at $1,429,417 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 146.47 on Friday. The firm has a market capitalization of $8.80 billion, a price-to-earnings ratio of 22.56 and a beta of 1.05. The company has a 50 day moving average price of $148.77 and a 200-day moving average price of $151.49. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.67 earnings per share. Equities analysts predict that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current year.

A number of equities research analysts have issued reports on JAZZ shares. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 30th. Mizuho cut Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $162.00 to $150.00 in a research report on Tuesday, July 4th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, August 29th. Deutsche Bank AG set a $178.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Monday, July 17th. Finally, Wells Fargo & Company reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC has an average rating of “Buy” and an average price target of $179.79.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.